In recent years, TIGIT has been investigated as an important checkpoint in cancer research focused on esophageal small cell carcinoma (32) and lung adenocarcinoma (33), where TIGIT-positive patients showed a shorter OS and a lower PFS than those of TIGIT-negative patients. This evidence concerns the gene TIGIT and cancer.